← FDA DRUG APPROVALS

FDA NDA · NDA210563

IMBRUVICA

ibrutinib

Sponsor: PHARMACYCLICS LLC

APPLICATION
NDA210563
TYPE
NDA
ORIGINAL APPROVAL
2018-02-16
LATEST ACTION
2025-10-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued, Prescription

Products

IMBRUVICA · ReferenceDiscontinued
IBRUTINIB 560MG · TABLET · ORAL
IMBRUVICA · ReferencePrescription
IBRUTINIB 280MG · TABLET · ORAL
IMBRUVICA · ReferencePrescription
IBRUTINIB 420MG · TABLET · ORAL
IMBRUVICA · ReferencePrescription
IBRUTINIB 140MG · TABLET · ORAL

Approval history

2025-10-21Labeling · Supplement 20 · standardLetterAP
2024-12-20Labeling · Supplement 19 · standardLetterAP
2024-05-09Labeling · Supplement 18 · 901 requiredLabelAP
2023-05-18Efficacy · Supplement 17 · standardLetterAP
2022-08-24Efficacy · Supplement 14 · priorityLabelAP
2022-08-24Efficacy · Supplement 12 · priorityLabelAP
2022-08-24Efficacy · Supplement 13 · priorityAP
2022-05-11Labeling · Supplement 11 · standardLetterAP
2020-12-22Labeling · Supplement 10 · standardLetterAP
2020-12-18Efficacy · Supplement 9 · standardLetterAP
2020-08-07Labeling · Supplement 7 · standardLetterAP
2020-04-21Efficacy · Supplement 6 · priorityLabelAP
2019-11-21Labeling · Supplement 4 · standardLabelAP
2019-07-15Labeling · Supplement 3 · standardLetterAP
2019-01-25Efficacy · Supplement 2 · priorityLabelAP
2018-08-24Efficacy · Supplement 1 · priorityLabelAP
2018-02-16Type 3 - New Dosage Form · Original · priorityLabelAP
2018-02-16Efficacy · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →